Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 31;43(10):BSR20231097.
doi: 10.1042/BSR20231097.

Src tyrosine kinase promotes cardiac remodeling induced by chronic sympathetic activation

Affiliations

Src tyrosine kinase promotes cardiac remodeling induced by chronic sympathetic activation

Wenqi Li et al. Biosci Rep. .

Abstract

Cardiac remodeling serves as the underlying pathological basis for numerous cardiovascular diseases and represents a pivotal stage for intervention. The excessive activation of β-adrenergic receptors (β-ARs) assumes a crucial role in cardiac remodeling. Nonetheless, the underlying molecular mechanisms governing β-AR-induced cardiac remodeling remain largely unresolved. In the present study, we identified Src tyrosine kinase as a key player in the cardiac remodeling triggered by excessive β-AR activation. Our findings demonstrated that Src mediates isoproterenol (ISO)-induced cardiac hypertrophy, fibrosis, and inflammation in vivo. Furthermore, Src facilitates β-AR-mediated proliferation and transdifferentiation of cardiac fibroblasts, and hypertrophy and cardiomyocytes in vitro. Subsequent investigations have substantiated that Src mediates β-AR induced the extracellular signal-regulated protein kinase (ERK1/2) signaling pathway activated by β-AR. Our research presents compelling evidence that Src promotes β-AR-induced cardiac remodeling in both in vivo and in vitro settings. It establishes the promoting effect of the β-AR/Src/ERK signaling pathway on overall cardiac remodeling in cardiac fibroblasts and underscores the potential of Src as a therapeutic target for cardiac remodeling.

Keywords: Src; cardiac remodeling; cardiomyocyte; β-adrenergic receptor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing interests associated with the manuscript.

Figures

Figure 1
Figure 1. Inhibition of Src attenuates ISO-induced cardiac hypertrophy
(A) Representative images of heart size. (B) Representative M-mode echocardiography images were taken to show left ventricular wall thickness. (C) Representative micrographs of myocyte cross-sectional area. Quantitative analysis of myocyte cross-sectional area; bar = 100 μm. F = 70.11, P<0.001. (D) Quantitative analysis of diastolic left ventricular posterior wall thickness; F = 50.20, P<0.001. (E) Quantitative analysis of HW/BW ratio; F = 32.23, P<0.001. (F) Quantitative analysis of HW/TL ratio; F = 65.61, P<0.001. (G) Quantitative analysis of ANP mRNA expression; F = 23.06, P<0.001. (H) Quantitative analysis of BNP mRNA expression; F = 27.61, P<0.001. (I) Left ventricular EF and (J) FS were measured to reflect cardiac contraction function; F(I) = 0.35, P(I)>0.05, F(J) = 0.17, P(J)>0.05. Data represent mean ± SEM. Analyzed by one-way analysis of variance (ANOVA) with Tukey’s post-hoc multiple comparison tests; N=7, *P<0.05, **P<0.01, ***P<0.001; ns, P>0.05.
Figure 2
Figure 2. Inhibition of Src prevents ISO-induced cardiac fibrosis
(A) Representative micrographs of picrosirius red-stained sections of the ventricle. Red parts represent collagen. The scale bars of 10× images are 2 mm, of 200× images are 100 μm. Quantification of cardiac interstitial collagen content from picrosirius red-stained sections with results expressed as the ratio of collagen area to heart area. There is no significance among all the groups; F = 35.76, P<0.001. (B) The mRNA expression of Collagen I in the heart tissue; F = 27.52, P<0.001. (C) The mRNA expression of Collagen III in the heart tissue; F = 42.56, P<0.001. Data represent mean ± SEM. Analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison tests; N=7, *P<0.05, ***P<0.001.
Figure 3
Figure 3. Inhibition of Src attenuates ISO-induced cardiac inflammation
(A) Representative images showing H&E staining of heart sections. The arrows refer to the infiltrated inflammatory cells. The scale bars of 10× images are 2 mm, of 200× images are 100 μm. (B) The mRNA expression of IL-1β in the heart tissue; F = 36.03, P<0.001. (C) The mRNA expression of IL-6 in the heart tissue; F = 73.46, P<0.001. Data represent mean ± SEM. Analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison tests; N=7, *P<0.05, **P<0.01, ***P<0.001.
Figure 4
Figure 4. Inhibition of Src reduces ISO-induced cardiomyocyte hypertrophy
(A) Src could be activated by isoproterenol. Cardiomyocytes were starved for 12 h, then stimulated with isoproterenol (10 μM) for 5 or 15 min, the phosphorylation of Src was analyzed using Western blotting. Activation of Src was determined by anti-Tyrosine 416 phospho-specific Src antibody. Experiments were performed in four times; F = 41.11, P<0.001. (B) The mRNA expression of ANP in the cardiomyocyte; F = 79.08, P<0.001. (C) The mRNA expression of BNP in the cardiomyocyte; F = 49.45, P<0.001. (D) Inhibition of Src reduces ISO-induced cardiomyocyte hypertrophy indicator F-actin. Cardiomyocytes were starved for 12 h, treated with or without PP1 (10 μM) for 1 h and then stimulated with isoproterenol (10 μM) in the presence or absence of PP1 for an additional 72 h; F = 67.44, P<0.001; bar = 50 μm. Data represent mean ± SEM. Analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison tests. N=4, number of NRCM>100 cells; *P<0.05, **P<0.01, ***P<0.001.
Figure 5
Figure 5. Src inhibition prevents ISO-induced cardiac fibroblast proliferation and transdifferentiation
(A) Src could be activated by isoproterenol. Cardiac fibroblasts were starved for 12 h, then stimulated with isoproterenol (10 μM) for 5 or 15 min, the phosphorylation of Src was analyzed using Western blotting. Activation of Src was determined by anti-Tyrosine 416 phospho-specific Src antibody. Experiments were performed in four times; F = 5.12, P<0.05. (B) Inhibition of Src prevents ISO-induced cardiac fibroblasts cell viability. The cell viability was detected by CCK-8 assay; F = 10.58, P<0.001. (C) Inhibition of Src reduces ISO-induced cardiac fibroblasts proliferation indicator PCNA; F = 10.48, P<0.01. (D) Inhibition of Src reduces ISO-induced cardiac fibroblasts transdifferentiation indicator α-SMA; F = 30.81, P<0.001. Cardiac fibroblasts were starved for 12 h, treated with or without PP1 (10 μM) for 1 h and then stimulated with isoproterenol (10 μM) in the presence or absence of PP1 for an additional 24 h. Data represent mean ± SEM. Analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison tests; N=4, *P<0.05, **P<0.01, ***P<0.001.
Figure 6
Figure 6. Src mediates β-AR-induced ERK1/2 signal pathway
(A) Inhibition of Src decreases ISO-induced ERK1/2 phosphorylation. HEK-293A was starved for 12 h, treated with or without PP1 (10 μM) for 1 h, then stimulated with isoproterenol (10 μM) for 5 or 15 min; F(interaction) = 9.06, P<0.01. (B) Overexpression of Src increases ISO-induced ERK1/2 phosphorylation. HEK-293A was transfected with flag-Src plasmid, starved for 12 h, then stimulated with isoproterenol (10 μM) for 5 or 15 min; F(interaction) = 8.59, P<0.01. Data represent mean ± SEM. Analyzed by two-way ANOVA with Tukey’s post-hoc multiple comparison tests; N=4, *P<0.05, **P<0.01, #P<0.05, ##P<0.01.

Similar articles

Cited by

References

    1. Bertero E. and Maack C. (2018) Metabolic remodelling in heart failure. Nat. Rev. Cardiol. 15, 457–470 10.1038/s41569-018-0044-6 - DOI - PubMed
    1. Frey N. and Olson E.N. (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65, 45–79, 10.1146/annurev.physiol.65.092101.142243 - DOI - PubMed
    1. Fu Y., Xiao H. and Zhang Y. (2012) Beta-adrenoceptor signaling pathways mediate cardiac pathological remodeling. Front. Biosci. (Elite Ed) 4, 1625–1637 10.2741/e484 - DOI - PubMed
    1. Steinberg S.F. (2018) Beta1-adrenergic receptor regulation revisited. Circ. Res. 123, 1199–1201, 10.1161/CIRCRESAHA.118.313884 - DOI - PMC - PubMed
    1. Savarese G., Bodegard J., Norhammar A., Sartipy P., Thuresson M., Cowie M.R.et al. . (2021) Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Eur. J. Heart Fail. 23, 1499–1511, 10.1002/ejhf.2271 - DOI - PubMed

Publication types

Substances